1
|
Barssotti L, Abreu ICME, Brandão ABP, Albuquerque RCMF, Ferreira FG, Salgado MAC, Dias DDS, De Angelis K, Yokota R, Casarini DE, Souza LB, Taddei CR, Cunha TS. Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice. Sci Rep 2021; 11:9189. [PMID: 33911129 PMCID: PMC8080591 DOI: 10.1038/s41598-021-88497-w] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 04/13/2021] [Indexed: 12/21/2022] Open
Abstract
Type 1 diabetes (T1DM) is a chronic disease characterized by hyperglycemia due to a deficiency in endogenous insulin production, resulting from pancreatic beta cell death. Persistent hyperglycemia leads to enhanced oxidative stress and liver injury. Several studies have evaluated the anti-diabetic and protective effects of probiotic strains in animal models. In the present study, we investigated, through histopathological and biochemical analyses, the effects of eight weeks of administration of Saccharomyces boulardii (S. boulardii) yeast on the liver of streptozotocin (STZ) induced diabetic C57BL/6 mice. Our results demonstrated that S. boulardii attenuates hepatocytes hydropic degeneration and hepatic vessels congestion in STZ-induced diabetic mice. The treatment attenuated the oxidative stress in diabetic mice leading to a reduction of carbonylated protein concentration and increased activity of antioxidant enzymes superoxide dismutase and glutathione peroxidase, compared to untreated diabetic animals. The results also show the beneficial influence of S. boulardii in regulating the hepatic concentration of renin angiotensin system (RAS) peptides. Therefore, our results demonstrated that S. boulardii administration to STZ-induced diabetic mice reduces oxidative stress and normalizes the concentration of RAS peptides, supporting the hypothesis that this yeast may have a role as a potential adjunctive therapy to attenuate diabetes-induced liver injury.
Collapse
Affiliation(s)
- Leticia Barssotti
- Department of Science and Technology, Federal University of São Paulo (Unifesp), São José dos Campos, Brazil
| | - Isabel C M E Abreu
- Department of Medicine, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Ana Beatriz P Brandão
- Department of Medicine, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | | | - Fabiana G Ferreira
- Department of Science and Technology, Federal University of São Paulo (Unifesp), São José dos Campos, Brazil
| | - Miguel A C Salgado
- Department of Bioscience and Oral Diagnosis, State University Julio de Mesquita Filho (Unesp), São José dos Campos, Brazil
| | - Danielle D S Dias
- Department of Physiology, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Kátia De Angelis
- Department of Physiology, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Rodrigo Yokota
- Department of Medicine, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Dulce E Casarini
- Department of Medicine, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Lívia B Souza
- Department of Medicine, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Carla R Taddei
- Department of Clinical and Toxicological Analyses, University of São Paulo (Usp), São Paulo, Brazil
| | - Tatiana S Cunha
- Department of Science and Technology, Federal University of São Paulo (Unifesp), São José dos Campos, Brazil.
- Federal University of São Paulo (Unifesp) - Institute of Science and Technology, Talim, 330 - Vila Nair, São José dos Campos, SP, 12231-280, Brazil.
| |
Collapse
|
2
|
Albuquerque RCMF, Brandão ABP, De Abreu ICME, Ferreira FG, Santos LB, Moreira LN, Taddei CR, Aimbire F, Cunha TS. Saccharomyces boulardii Tht 500101 changes gut microbiota and ameliorates hyperglycaemia, dyslipidaemia, and liver inflammation in streptozotocin-diabetic mice. Benef Microbes 2019; 10:901-912. [PMID: 31965836 DOI: 10.3920/bm2019.0056] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Type 1 diabetes mellitus (T1DM) is a disorder resulting from chronic autoimmune destruction of insulin-producing pancreatic β-cells, lack of insulin production and hyperglycaemia. The aim of this study was to evaluate the hypothesis that streptozotocin-diabetic mice treated with Saccharomyces boulardii THT 500101 strain present improvement of glucose and triglycerides metabolism, reduction of liver inflammation concomitant with a beneficial impact in the gut microbiota profile. C57BL/6 male mice were randomly assigned into three groups: Control, Diabetes, Diabetes+Probiotic, and were euthanised 8 weeks after probiotic chronic administration. Mice submitted to treatment presented reduced glycemia in comparison with the diabetic group, which was correlated with an increase in C-peptide level and in hepatic glycogen content. Fat metabolism was significantly altered in streptozotocin-induced diabetic group, and S. boulardii treatment regulated it, leading to a decrease in serum triglycerides secretion, increase in hepatic triglycerides storage and modulation of inflammatory profile. The phenotypic changes seen from chronic S. boulardii treatment were found to be broadly associated with the changes in microbioma of diabetic animals, with increased proportion in Bacteroidetes, Firmicutes and Deferribacteres, and a decreased proportion of Proteobacteria and Verrucomicrobia phylum. Thus, the data presented here show up a novel potential therapeutic role of S. boulardii for the treatment and attenuation of diabetes-induced complications.
Collapse
Affiliation(s)
- R C M F Albuquerque
- Federal University of São Paulo (Unifesp), Department of Medicine - São Paulo, Sp. Rua Pedro De Toledo 720 - 2° Andar, Vila Clementino, 04039-002 São Paulo, SP, Brazil
| | - A B P Brandão
- Federal University of São Paulo (Unifesp), Department of Medicine - São Paulo, Sp. Rua Pedro De Toledo 720 - 2° Andar, Vila Clementino, 04039-002 São Paulo, SP, Brazil
| | - I C M E De Abreu
- Federal University of São Paulo (Unifesp), Department of Medicine - São Paulo, Sp. Rua Pedro De Toledo 720 - 2° Andar, Vila Clementino, 04039-002 São Paulo, SP, Brazil
| | - F G Ferreira
- Federal University of São Paulo (Unifesp), Institute of Science and Technology, Department of Science and Technology - São José Dos Campos, Rua Talim 330. Vila Nair, 12231-280 São José Dos Campos, SP, Brazil
| | - L B Santos
- Federal University of São Paulo (Unifesp), Institute of Science and Technology, Department of Science and Technology - São José Dos Campos, Rua Talim 330. Vila Nair, 12231-280 São José Dos Campos, SP, Brazil
| | - L N Moreira
- University of São Paulo (Usp), School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses - São Paulo, Avenida Professor Lineu Prestes, 580. Cidade Universitária, 05508-000 São Paulo, SP, Brazil
| | - C R Taddei
- University of São Paulo (Usp), School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses - São Paulo, Avenida Professor Lineu Prestes, 580. Cidade Universitária, 05508-000 São Paulo, SP, Brazil
| | - F Aimbire
- Federal University of São Paulo (Unifesp), Institute of Science and Technology, Department of Science and Technology - São José Dos Campos, Rua Talim 330. Vila Nair, 12231-280 São José Dos Campos, SP, Brazil
| | - T S Cunha
- Federal University of São Paulo (Unifesp), Institute of Science and Technology, Department of Science and Technology - São José Dos Campos, Rua Talim 330. Vila Nair, 12231-280 São José Dos Campos, SP, Brazil
| |
Collapse
|